Blog
RSS FeedPosted by Michael Wonder on 06 Dec 2024
NICE describes how weight loss drug tirzepatide will be rolled out
5 December 2024 - The medication will initially be offered only to those people with the highest clinical needs. ...
Posted by Michael Wonder on 06 Dec 2024
Positive CHMP opinion for the extension of indication of Palforzia for the treatment of toddlers with confirmed peanut allergy
2 December 2024 - Stallergenes Greer today announced that the CHMP of the EMA provided a positive opinion for the extension ...
Posted by Michael Wonder on 06 Dec 2024
Does NICE’s “severity modifier” for assessing diseases need to change?
22 November 2024 - Breast cancer charities and patients are “devastated” that the drug Enhertu will not be available in ...
Posted by Michael Wonder on 06 Dec 2024
Agenda for the December 2024 PBAC intracycle meeting
6 December 2024 - The agenda for the December 2024 PBAC intracycle meeting is now available. ...
Posted by Michael Wonder on 05 Dec 2024
Canada’s Drug Agency launches consultation on methods guide
28 November 2024 - Canada’s Drug Agency is launching a consultation on its first ever methods guide. ...
Posted by Michael Wonder on 05 Dec 2024
MSAC publishes agenda for April 2025 MSAC meeting
27 November 2024 - - The MSAC Secretariat has published a list of applications scheduled to be considered by the ...
Posted by Michael Wonder on 05 Dec 2024
Orphelia Pharma provides update on the regulatory submission of Kizfizo with the EMA
18 November 2024 - Orphelia to seek re-examination following CHMP negative opinion for the treatment of relapsed or refractory high-risk ...
Posted by Michael Wonder on 05 Dec 2024
Results of health technology assessments of orphan drugs in Germany—lack of added benefit, evidence gaps, and persisting unmet medical needs
3 December 2024 - The number of orphan drug approvals has increased sharply in Europe. In Germany, all orphan drugs are ...
Posted by Michael Wonder on 04 Dec 2024
Fedratinib dihydrochloride monohydrate for the treatment of adults with disease-related splenomegaly or symptoms in myelofibrosis
20 November 2024 - NICE has published final evidence-based recommendations on the use of fedratinib dihydrochloride monohydrate (Inrebic) for the ...
Posted by Michael Wonder on 03 Dec 2024
HTA Policy and Methods Review update
3 December 2024 - The Minister for Health and Aged Care, the Hon Mark Butler MP has announced the Implementation Advisory ...
Posted by Michael Wonder on 02 Dec 2024
Gilead’s Trodelvy awaits re-deliberation for reimbursement in Korea following patient petitions, price cut proposal
25 November 2024 - The triple negative breast cancer treatment Trodelvy (sacituzumab govitecan), which drew 100,000 petitions from patients, will ...
Posted by Michael Wonder on 01 Dec 2024
Update on the March 2025 meeting
28 November 2024 - As announced by the Minister on 6 November 2024, to process the unprecedented number of submissions for ...
Posted by Michael Wonder on 01 Dec 2024
Agenda for the March 2025 PBAC meeting (version 1)
28 November 2024 - The agenda for the March 2025 PBAC meeting is now available. ...
Posted by Michael Wonder on 30 Nov 2024
NICE responds to failure of talks to reach price agreement on Enhertu
19 November 2024 - Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu ...
Posted by Michael Wonder on 29 Nov 2024
Update from the PBAC (November 2024)
28 November 2024 - An update from the Chair and Deputy Chair of the PBAC is now available. ...